Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma.
作者信息
Lee Ji Yeon, Sung Pil Soo
机构信息
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul, Korea.
出版信息
Gut Liver. 2024 Jul 15;18(4):558-559. doi: 10.5009/gnl240274.
Abstract
摘要
相似文献
1
Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma.
Gut Liver. 2024 Jul 15;18(4):558-559. doi: 10.5009/gnl240274.
2
Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.
Gut Liver. 2024 Jul 15;18(4):709-718. doi: 10.5009/gnl240085. Epub 2024 Jun 27.
3
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Anticancer Res. 2022 Mar;42(3):1403-1412. doi: 10.21873/anticanres.15610.
4
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait.
Immunotherapy. 2021 Jun;13(8):637-644. doi: 10.2217/imt-2021-0026. Epub 2021 Apr 6.
5
Considering nutritional status to improve outcomes of patients treated by atezolizumab-bevacizumab for advanced hepatocellular carcinoma.
Liver Int. 2024 Jun;44(6):1276-1277. doi: 10.1111/liv.15887.
6
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
7
Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab.
Liver Int. 2024 Jul;44(7):1735. doi: 10.1111/liv.15944. Epub 2024 May 8.
8
Three effective cases of transcatheter arterial embolization after atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a case report.
J Med Case Rep. 2025 Jan 27;19(1):38. doi: 10.1186/s13256-025-05040-5.
9
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.
Clin Mol Hepatol. 2022 Jul;28(3):575-579. doi: 10.3350/cmh.2022.0047. Epub 2022 Apr 21.
10
Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Cancer Commun (Lond). 2020 Dec;40(12):743-745. doi: 10.1002/cac2.12110. Epub 2020 Nov 7.
本文引用的文献
1
Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.
Gut Liver. 2024 Jul 15;18(4):709-718. doi: 10.5009/gnl240085. Epub 2024 Jun 27.
2
Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of HCC.
Hepatology. 2024 Nov 1;80(5):1074-1086. doi: 10.1097/HEP.0000000000000772. Epub 2024 Feb 15.
3
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
Clin Mol Hepatol. 2024 Apr;30(2):177-190. doi: 10.3350/cmh.2023.0426. Epub 2023 Dec 29.
4
Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.
Int J Mol Sci. 2023 Jul 22;24(14):11799. doi: 10.3390/ijms241411799.
5
Radiologic features of hepatocellular carcinoma related to prognosis.
J Liver Cancer. 2023 Mar;23(1):143-156. doi: 10.17998/jlc.2023.02.16. Epub 2023 Mar 9.
6
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison.
Clin Mol Hepatol. 2023 Apr;29(2):252-262. doi: 10.3350/cmh.2023.0099. Epub 2023 Mar 10.
7
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.
Clin Mol Hepatol. 2023 Apr;29(2):277-292. doi: 10.3350/cmh.2022.0212. Epub 2023 Jan 30.
8
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12.
9
Hepatocellular carcinoma.
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
10
The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.
Cancer Treat Rev. 2013 Aug;39(5):534-40. doi: 10.1016/j.ctrv.2012.08.003. Epub 2012 Sep 17.
Zotero 插件